ALGS FY 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-44.6% YoY

Gross Profit

$1M57.5% margin

Operating Income

-$88M-4024.9% margin

Net Income

-$24M-1106.7% margin

EPS (Diluted)

$-2.45

Cash Flow

Operating Cash Flow

-$83M

Free Cash Flow

-$83M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$89M

Total Liabilities

$35M

Stockholders' Equity

$54M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-44.6%
Gross Profit	$1M	$4M	-68.2%
Operating Income	-$88M	-$89M	+1.3%
Net Income	-$24M	-$131M	+81.6%